ÂÜÀòÂÒÂ×

James Kalabus is an accomplished professional in the field of translational and clinical pharmacology, currently serving as the Head of Translational & Clinical Pharmacology at Inhibrx, Inc. since August 2019. Prior to this role, James held significant positions at Amgen as Principal Scientist, focusing on immuno-oncology programs, and at Novartis, where James progressed from Scientist I to Investigator III within the Clinical Pharmacology team. Academic experience includes a postdoctoral fellowship at the University at Buffalo, collaborating with Roswell Park Cancer Institute on doxorubicin-induced cardiotoxicity and population pharmacokinetics. James earned a PhD in Pharmaceutical Sciences from the University at Buffalo and holds a BS in Biology from the University of Wyoming and a background in Human Biology from Michigan State University.